Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Nautilus Biotechnology (NASDAQ: NAUT), a company focused on single molecule protein analysis platforms, has scheduled its Q4 and full year 2024 financial results announcement for February 27, 2025, before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT), a company focused on single molecule protein analysis platforms, has scheduled its Q4 and full year 2024 financial results announcement for February 27, 2025, before market open. The company will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on the same day to discuss results, business developments, and outlook. Investors can access the live audio webcast through the company's website.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was -3.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2024 before market open on Thursday, February 27, 2025.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.